Background: A dual angiotensin type 1 receptor blocker (ARB)/peroxisome proliferator-activated receptor-␥ (PPAR␥) agonist telmisartan may be more useful for microalbuminuria reduction than ARBs with no PPAR␥ agonistic action. We investigated whether there is a difference between the effects of telmisartan and valsartan with respect to microalbuminuria reduction, and the association with improvement of metabolic features or suppression of the inflammatory state.
M
etabolic syndrome is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. 1 Microalbuminuria, which is an independent risk factor for renal and CVDs, is closely associated with metabolic syndrome with a graded relationship between the number of components of metabolic syndrome and those corresponding values. 2, 3 Because patients who achieved microalbuminuria reduction have proportionally fewer kidney and CVD events, microalbuminuria may be useful, not only as cardiovascular risk stratification, but also as a clinical tool to assess the success of interventions to the metabolic syndrome. 3 Renin-angiotensin-aldosterone system (RAAS) blockade (by angiotensin type 1 receptor blockers [ARBs] or angiotensin-converting enzyme [ACE] inhibitors) may be ideal, because RAAS blockade can reduce microalbuminuria to a greater extent than can be accounted for by blood pressure (BP)-lowering effects. [3] [4] [5] However, RAAS blockers are not completely adequate for such treatment; 6, 7 therefore, additional strategies are needed. Recently, some ARBs (telmisartan, irbesartan) have been shown to act as a partial peroxisome proliferator-activated receptor-␥ (PPAR␥) agonist. 8, 9 Because PPAR␥ plays an important role, not only in improving glucose and lipid homeostasis, but also in the inhibition of vascular inflammation, oxidative stress, and atherosclerosis, the dual ARB/PPAR␥ agonist telmisartan may be more useful for microalbuminuria reduction.
Until now, it has been reported that telmisartan had more favorable effects on glucose or lipid parameters and antiinflammation than other ARBs with no PPAR␥ agonist in hypertensives with diabetes. 10 -12 Vitale et al 10 showed that telmisartan had more insulin sensitizing activity than losartan in patients with metabolic syndrome. But no investigator had examined whether the magnitude of the favorable effects of telmisartan is sufficient to produce clinically relevant microalbuminuria reduction. In this study, 53 patients with metabolic syndrome taking the no-PPAR␥ agonistic ARB valsartan were recruited, and in 30 of these patients valsartan was randomly replaced by telmisartan. We then investigated whether there was a difference between the effects of telmisartan and valsartan with respect to microalbuminuria reduction through improvement of metabolic factors or suppression of the inflammatory state.
Methods

Study Population and Data Collection
This was an open-label, randomized, controlled, with two parallel groups, 12-week study. Fifty-three patients with metabolic syndrome were recruited from multiple centers in Japan. Metabolic syndrome was defined using revised ATP III criteria 13 with recommended ethnic modifications in waist circumference.
14 Because all subjects had hypertension and were treated with valsartan, metabolic syndrome was diagnosed in patients who met at least two of the following criteria: (1) waist circumference Ն85 cm in men, Ն90 cm in women; (2) fasting glucose Ն100 mg/dL; (3) HDL Ͻ40 mg/dL in men, Ͻ50 mg/dL in women; and (4) triglyceride (TG) Ն150 mg/dL. Taking medication for these diseases was considered to fulfill the criteria. Diabetes was defined as use of an oral antihyperglycemic agent or having a fasting glucose of Ն126 mg/dL. All subjects were taking valsartan at a stable dose for at least 6 months, and other antihypertensive drugs (Table 1) had remained unchanged for 3 months. For inclusion in the study therapy for hyperglycemia and dyslipidemia (Table 1) , patients must have been kept at the same dose for the previous 6 months, but patients who received thiazolidinediones or metformin were excluded. All of the sub- jects enrolled were randomly assigned to replace valsartan by telmisartan (switch valsartan 40 mg, 80 mg, 160 mg, for telmisartan 20 mg, 40 mg, 80 mg, respectively) or to keep taking valsartan (control group). After randomization, our participants were required to continue taking the same dose of any concomitant drugs (Table 1) throughout the study. No drug titration for blood pressure (BP), blood glucose, and lipids were required during the entire study. At baseline and 12 weeks of treatment, anthropometric parameters, BP, and the following parameters were measured: glucose (glucose, insulin, homeostasis model assessment [HOMA-IR]) and lipid parameters (TG, HDL, total cholesterol, LDL, remnant lipoprotein [RLP]), highsensitivity C-reactive protein (hs-CRP), high molecular weight (HMW) adiponectin, and microalbuminuria. Waist and hip circumferences were measured at the level of the umbilicus and the trochanter, respectively. Systolic BP (Korotkoff phase 54) and diastolic BP (Korotkoff phase V) were measured using a mercury sphygmomanometer, with subjects in the sitting position after at least 5 min of rest. Three measurements were taken 1 min apart, and the mean of the last two readings was used for calculation. The participants were told by their physicians to adhere to their usual diet and lifestyle during the study. Exclusion criteria were as follows: contraindication to telmisartan; history of myocardial infarction, unstable angina, cerebrovascular events (stroke, transient ischemic attack), heart failure in the past 6 months; severe hepatic and renal disease (creatinine [Cr] Ն3 mg/dL); and body weight change of more than 10% in the past 3 months. The study protocol was approved by the internal review board of Jichi Medical University School of Medicine, and all patients gave written informed consent.
Laboratory Assays
Venous blood samples were obtained between 8:00 and 9:00 AM after an overnight fast. Insulin sensitivity was quantified using HOMA-IR (plasma insulin ϫ plasma glucose) / 405. 15 Remnant lipoprotein was analyzed by an immunoseparation method (Jimro; Otsuka Pharmaceutical Co. Ltd., Japan). 16 High molecular weight adiponectin concentrations were measured using a two-step sandwich ELISA system (FujiRevio Inc., Tokyo, Japan). The Hs-CRP was measured with an ultra high sensitivity latex turbidimetric immunoassay (Behring Nephelometry; SRL, Japan). Microalbuminuria, defined by the urine albuminto-urine creatinine ratio (UACR) in morning spot urine samples, was analyzed by the immunoturbidimetric method (LX reagent "Eiken" Alb II; Eiken Chemical Company, Tokyo, Japan). The intraassay and interassay coefficients of variation between the samples were as Data are expressed as mean Ϯ SE or median (25th to 75th percentile). The % change was calculated by ([12 week raw data -baseline raw data] / baseline raw data ϫ 100) and described as mean % change, but the variables with asterisks were described as median % changes. Glomerular filtration rate (GFR) was estimated by the Cockcroft-Gault equation: (140 -age) ϫ weight / 2 ϫ Cr ϫ 0.85 (if women).
† P values were calculated by paired Student s t-test for the change between baseline and that after the 12 weeks. Variables with asterisks are skewed and were logarithmically transformed before analysis; ‡ P values were calculated for the mean % changes in variables over time and between the groups assessed by nonpaired Student s t-test (valsartan v telmisartan). Statistical significance was defined as P Ͻ .05. follows: hs-CRP, 2.3% and 3.0%; UACR, 3.7% and 0%; HMW adiponectin, both Ͻ15%, respectively.
Statistical Analysis
Data are expressed as mean Ϯ SE or median (range, 25th to 75th percentile). Significant baseline differences between groups were determined by the unpaired Student's t-test. Categorical data were compared by the 2 test. The Student's t-test was used to compare parameter changes over time and between groups. Variables with skewed distribution were logarithmically transformed before analysis. Simple regression analysis was performed to assess the linear relationship between the various parameters, and multivariable regression analysis was also performed to determine associated factors in microalbuminuria reduction. Statistical significance was defined as P Ͻ .05. All calculations were performed with SPSS version 11.0 software (SPSS, Inc., Chicago, IL).
Results
Baseline parameters were well matched in both groups (Table 1) . A total of 49 patients successfully completed the study. Two patients were excluded at baseline, because one subject had hs-CRP level Ͼ10 mg/L, which suggested the presence of inflammation, and the other was using pioglitazone. Two patients failed to complete the study. The main reasons were the participants' wishes (Fig. 1) . There was no significant change in anthropometric factors during the study. No adverse effects were seen in the telmisartan group.
Blood Pressure and Metabolic Parameters
There was no significant change in office BP in both groups (Table 2 ). Glucose and lipid parameters were unchanged in both groups ( Table 2 ). The HMW adiponectin was significantly increased in the telmisartan group (4.6 v 5.0 g/mL, P ϭ .024; Table 2), whereas it was not changed in the control group (4.4 v 3.5 g/mL, P ϭ .428; Table 2 ). No significant changes were recognized in any metabolic parameters in parallel with the HMW adiponectin elevation (data not shown).
Inflammation and Microalbuminuria
There were significant reductions of UACR and hs-CRP in the telmisartan group (28.1 v 18.9 mg/g ⅐ Cr and 0.77 v 0.60 mg/L, respectively, P ϭ .001 and P ϭ .022) but not in the control group (22.8 v 27.2 mg/g ⅐ Cr and 0.78 v 0.70 mg/L, respectively, P ϭ .447 and P ϭ .324; Table 2 ). Even after adjustment for confounding factors, such as gender and alcohol intake, it remains unchanged, with a significant reduction of hs-CRP (P ϭ .018), and a decreased tendency in UACR (P ϭ .055) in the telmisartan group. The change of UACR was correlated with the change of hs-CRP levels (r ϭ 0.413, P ϭ .003; Fig. 2 ), but none of the other parameters, including systolic BP (r ϭ 0.061, P ϭ .671), diastolic BP (r ϭ 0.057, P ϭ .694), glucose (r ϭ 0.115, P ϭ .420), glycosylated hemoglobin (HbA lc ) (r ϭ 0.046, P ϭ .747), total cholesterol (r ϭ Ϫ0.250, P ϭ .076), TG (r ϭ 0.021, P ϭ .886), and HMW adiponectin (r ϭ Ϫ0.088, P ϭ .537), was correlated with UACR reduction. Multivariable regression analysis was used to examine whether the association between UACR and hs-CRP is independent of other confounding factors, such as total cholesterol, and the relationship remains unchanged (␤ ϭ 0.382, P ϭ .005). These results were also recognized both in diabetic patients (n ϭ 13; UACR, 84.4 v 27 mg/g ⅐ Cr and hs-CRP, 0.69 v 0.56 mg/L, respectively, P ϭ .01 and P ϭ .029) and nondiabetic patients (n ϭ 17; UACR, 25.7 v 18.9 mg/g ⅐ Cr and hs-CRP, 1.1 v 0.65 mg/L, respectively, P ϭ .03 and P ϭ .056). And there were significant reductions of UACR and hs-CRP in the 40 mg/d (n ϭ 21) and 80 mg/d (n ϭ 1) telmisartan dose, whereas no significant changes existed in the UACR and hs-CRP level in the 20 mg/d telmisartan dose (n ϭ 8; Table 3 ).
Discussion
In this study we showed that in hypertensive patients with metabolic syndrome, telmisartan reduced microalbuminuria more effectively than valsartan, possibly through suppression of the inflammatory state. These results were also recognized in the study patients with or without diabetes. Because our participants had already been taking valsartan, our results might be due to additional effects beyond the RAAS blockade.
Microalbuminuria Reduction and Antiinflammatory Effects
Telmisartan showed more microalbuminuria reduction in metabolic hypertensive patients compared with valsartan, possibly by the suppression of the inflammatory state. In Data are expressed as mean Ϯ SE or median (25th to 75th percentile). The % change was calculated by ([12 weeks raw data Ϫ baseline raw data] / baseline raw data ϫ 100) and described as mean % change, but the variables with asterisks were described as median % changes.
† P values were calculated by paired Student s t-test for the change between baseline and that after the 12 weeks. Variables with asterisks are skewed and were logarithmically transformed before analysis; ‡ P values were calculated for the mean % changes in variables over time and between the groups assessed by nonpaired Student s t-test (valsartan v telmisartan). Statistical significance was defined as P Ͻ .05.
contrast to a previous report, 17 neither BP nor any metabolic parameter changes were related with microalbuminuria reduction. Some studies reported that chronic inflammatory state was involved in the development of microalbuminuria, but to the best of our knowledge, they did not show the possibility that an inhibition of chronic inflammatory state led to microalbuminuria reduction. 17, 18 The reasons why telmisartan could have more microalbuminuria reduction and antiinflammatory effect than valsartan were beyond the scope of our study, but some unique characteristics of telmisartan, including PPAR␥ agonist, antioxidative, or lipophilic effects, might be involved. 6, 7, 19 
Metabolic Parameters
In contrast to previous reports, 10 -12 we found no significant effects on glucose or lipid parameters in the telmisartan group. The inconsistence of our results may stem from the fact that our patients were well controlled regarding glucose or lipid status, and also because of the small sample size causing a low power to detect metabolic changes as well as the low doses of telmisartan used in the study. In a previous study showing the positive effects on insulin-sensitizing activity in patients with metabolic syndrome, telmisartan was given at 80 mg/d. 10 In our study, only one patient received 80 mg/d and the dosing schedule should be acknowledged as a possible reason for failing to detect effects, because the metabolic effects of telmisartan were dose dependent. 12 HMW adiponectin was upregulated by telmisartan. Previously, a few reports showed that telmisartan could increase the total adiponectin level in vivo 11 or in vitro, 20, 21 but our study is the first to show a specific increase of the HMW form of adiponectin in vivo. The precise mechanisms are unclear, but several possible reasons have been proposed. First, telmisartan has more robust effects on adipocyte differentiation in vitro than valsartan through PPAR␥ agonistic effects or its high lipophilic properties. 19, 21 Second, telmisartan has a strong binding affinity to angiotensin II type 1 receptor allowing angiotensin II to cause prolonged stimulation of angiotensin II type 2 receptor, which is postulated to play an important role for HMW adiponectin production.
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Study Limitation
There are some limitations to this study. First, we enrolled a small number of subjects. Second, the one-time measurement of various parameters is an important limitation because of the susceptibility to intraindividual variation. Third, we evaluated BP by office measurement, and differences in antihypertensive effects are likely to be overestimated, especially in the morning period; therefore, subtle differences in out-of office BP cannot be ruled out in the reduction of microalbuminuria.
23
Conclusions
The dual ARB/PPAR␥ agonist telmisartan elevated HMW adiponectin and reduced microalbuminuria, possibly through the suppression of low-grade inflammation in metabolic hypertensive patients. Whether the magnitude of the observed effect of telmisartan is sufficient to produce clinically relevant cardiovascular benefits is an open question, and the ongoing large clinical trial, ONTARGET, could answer this question. 24 
